Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.

With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.

The US biosimilar market for Neulasta, one of the few ‘maturing’ markets with multiple biosimilar entrants, suggests that commercial strategy more than price is of greater importance as sponsors look to prize market share from Amgen – reflecting the chasm between certain biosimilar and traditional generic markets.

The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.